UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical On Path To Long-Term Upside
December 11, 2014 at 10:04 AM EST
In a report published Thursday, UBS Securities analyst Andrew Peters reiterated a Buy rating on BioMarin Pharmaceutical (NASDAQ: BMRN), ...